Annual CFO
-$45.78 M
+$9.45 M+17.10%
December 31, 2023
Summary
- As of February 8, 2025, OVID annual cash flow from operations is -$45.78 million, with the most recent change of +$9.45 million (+17.10%) on December 31, 2023.
- During the last 3 years, OVID annual CFO has risen by +$5.80 million (+11.25%).
- OVID annual CFO is now -138.60% below its all-time high of $118.61 million, reached on December 31, 2021.
Performance
OVID Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$15.01 M
-$752.00 K-5.28%
September 30, 2024
Summary
- As of February 8, 2025, OVID quarterly cash flow from operations is -$15.01 million, with the most recent change of -$752.00 thousand (-5.28%) on September 30, 2024.
- Over the past year, OVID quarterly CFO has dropped by -$3.10 million (-25.99%).
- OVID quarterly CFO is now -109.33% below its all-time high of $160.90 million, reached on March 31, 2021.
Performance
OVID Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$57.86 M
-$4.96 M-9.37%
September 30, 2024
Summary
- As of February 8, 2025, OVID TTM cash flow from operations is -$57.86 million, with the most recent change of -$4.96 million (-9.37%) on September 30, 2024.
- Over the past year, OVID TTM CFO has dropped by -$12.08 million (-26.38%).
- OVID TTM CFO is now -145.30% below its all-time high of $127.73 million, reached on March 31, 2021.
Performance
OVID TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
OVID Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.1% | -26.0% | -26.4% |
| 3 y3 years | +11.3% | -26.0% | -26.4% |
| 5 y5 years | -0.5% | -26.0% | -26.4% |
OVID Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -138.6% | +17.1% | -63.5% | +25.3% | -148.8% | +7.2% |
| 5 y | 5-year | -138.6% | +17.1% | -109.3% | +25.3% | -145.3% | +7.2% |
| alltime | all time | -138.6% | +17.1% | -109.3% | +25.3% | -145.3% | +7.2% |
Ovid Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$15.01 M(+5.3%) | -$57.86 M(+9.4%) |
| Jun 2024 | - | -$14.26 M(-14.6%) | -$52.90 M(+5.1%) |
| Mar 2024 | - | -$16.69 M(+40.1%) | -$50.35 M(+10.0%) |
| Dec 2023 | -$45.78 M(-17.1%) | -$11.91 M(+18.5%) | -$45.78 M(+6.4%) |
| Sep 2023 | - | -$10.05 M(-14.1%) | -$43.05 M(-5.7%) |
| Jun 2023 | - | -$11.71 M(-3.4%) | -$45.67 M(-3.3%) |
| Mar 2023 | - | -$12.11 M(+32.0%) | -$47.25 M(-14.4%) |
| Dec 2022 | -$55.23 M(-146.6%) | -$9.18 M(-27.6%) | -$55.23 M(-4.9%) |
| Sep 2022 | - | -$12.68 M(-4.6%) | -$58.05 M(+3.2%) |
| Jun 2022 | - | -$13.29 M(-33.8%) | -$56.25 M(-9.8%) |
| Mar 2022 | - | -$20.09 M(+67.4%) | -$62.37 M(-152.6%) |
| Dec 2021 | $118.61 M(-329.9%) | -$12.00 M(+10.4%) | $118.61 M(+2.2%) |
| Sep 2021 | - | -$10.87 M(-44.0%) | $116.10 M(-7.5%) |
| Jun 2021 | - | -$19.42 M(-112.1%) | $125.50 M(-1.7%) |
| Mar 2021 | - | $160.90 M(-1208.9%) | $127.73 M(-347.6%) |
| Dec 2020 | -$51.58 M | -$14.51 M(+887.4%) | -$51.58 M(-4.4%) |
| Sep 2020 | - | -$1.47 M(-91.5%) | -$53.96 M(-12.9%) |
| Jun 2020 | - | -$17.19 M(-6.6%) | -$61.99 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$18.41 M(+9.0%) | -$56.64 M(+10.9%) |
| Dec 2019 | -$51.09 M(+12.1%) | -$16.89 M(+77.9%) | -$51.09 M(+13.1%) |
| Sep 2019 | - | -$9.49 M(-19.8%) | -$45.17 M(-1.2%) |
| Jun 2019 | - | -$11.84 M(-8.0%) | -$45.72 M(+0.5%) |
| Mar 2019 | - | -$12.87 M(+17.3%) | -$45.50 M(-0.1%) |
| Dec 2018 | -$45.56 M(+44.8%) | -$10.97 M(+9.2%) | -$45.56 M(+4.5%) |
| Sep 2018 | - | -$10.05 M(-13.5%) | -$43.60 M(+1.7%) |
| Jun 2018 | - | -$11.62 M(-10.1%) | -$42.87 M(+15.1%) |
| Mar 2018 | - | -$12.93 M(+43.5%) | -$37.24 M(+18.3%) |
| Dec 2017 | -$31.47 M(+76.8%) | -$9.01 M(-3.4%) | -$31.47 M(+11.7%) |
| Sep 2017 | - | -$9.32 M(+55.7%) | -$28.18 M(+19.9%) |
| Jun 2017 | - | -$5.99 M(-16.4%) | -$23.49 M(+11.3%) |
| Mar 2017 | - | -$7.16 M(+25.3%) | -$21.11 M(+18.6%) |
| Dec 2016 | -$17.80 M(+224.5%) | -$5.71 M(+23.2%) | -$17.80 M(+47.3%) |
| Sep 2016 | - | -$4.64 M(+28.4%) | -$12.09 M(+62.2%) |
| Jun 2016 | - | -$3.61 M(-6.1%) | -$7.45 M(+93.9%) |
| Mar 2016 | - | -$3.84 M | -$3.84 M |
| Dec 2015 | -$5.49 M | - | - |
FAQ
- What is Ovid Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Ovid Therapeutics?
- What is Ovid Therapeutics annual CFO year-on-year change?
- What is Ovid Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Ovid Therapeutics?
- What is Ovid Therapeutics quarterly CFO year-on-year change?
- What is Ovid Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Ovid Therapeutics?
- What is Ovid Therapeutics TTM CFO year-on-year change?
What is Ovid Therapeutics annual cash flow from operations?
The current annual CFO of OVID is -$45.78 M
What is the all time high annual CFO for Ovid Therapeutics?
Ovid Therapeutics all-time high annual cash flow from operations is $118.61 M
What is Ovid Therapeutics annual CFO year-on-year change?
Over the past year, OVID annual cash flow from operations has changed by +$9.45 M (+17.10%)
What is Ovid Therapeutics quarterly cash flow from operations?
The current quarterly CFO of OVID is -$15.01 M
What is the all time high quarterly CFO for Ovid Therapeutics?
Ovid Therapeutics all-time high quarterly cash flow from operations is $160.90 M
What is Ovid Therapeutics quarterly CFO year-on-year change?
Over the past year, OVID quarterly cash flow from operations has changed by -$3.10 M (-25.99%)
What is Ovid Therapeutics TTM cash flow from operations?
The current TTM CFO of OVID is -$57.86 M
What is the all time high TTM CFO for Ovid Therapeutics?
Ovid Therapeutics all-time high TTM cash flow from operations is $127.73 M
What is Ovid Therapeutics TTM CFO year-on-year change?
Over the past year, OVID TTM cash flow from operations has changed by -$12.08 M (-26.38%)